Curing Cancer
- Jeanna Winchester PhD
- Mar 18
- 17 min read
Updated: May 18
It's less Science Fiction and more Science Fact.
March 15, 2026
Cancer has touched nearly every life in the world, whether directly or indirectly. It is rare to meet someone who hasn’t been profoundly affected by this disease, and my own family history is a testament to that reach. In my family, every single woman, except my mother and her sister, has lost their life to ovarian, uterine, or breast cancer.
While we have tested negative for the known BRCA mutations, it is clear that some yet-to-be-identified genetic factor has been moving through our bloodline for generations. That tragic precedent finally stopped with my mother and her sister, who both battled cancer and luckily, won; largely made possible by the incredible advancements in how we are Curing Cancer.
Given that personal history, I want to explore this landscape with you, moving beyond the fear and into the science. I am lucky because of the researchers who work day and night to fight cancer.
In this editorial, we are going to break down what cancer actually is and what the overall risk looks like for people today. From there, we will dive into the most exciting, cutting-edge treatments currently changing the game, before concluding with a Human Verified Reality Check: how the latest science meets the costly realities of surviving cancer.
How Did They Survive Cancer?
Well, it’s complicated, and quite a bit of luck is involved. Cancer is not a single illness but a complex collection of over 200 distinct conditions. It arises when genetic mutations disrupt the body’s regulatory systems, which manage how cells divide, specialize, and die. This all leads to the uncontrolled growth and spread of abnormal tissue.
The scope of this challenge remains massive. In the United States alone, we are projecting over 2.1 million new cancer diagnoses in 2026, averaging roughly 5,800 cases daily. Unfortunately, we also expect about 626,140 cancer-related deaths this year, or nearly 1,720 per day. Lung cancer continues to be the most fatal, with its projected death toll exceeding that of colorectal and pancreatic cancers combined.
Despite these sobering statistics, we have achieved extraordinary progress. Since 1991, the overall cancer death rate in the U.S. has dropped by roughly 34%, effectively averting nearly 5 million deaths. This success is driven by a combination of reduced smoking, enhanced early detection through screening, and the rise of transformative treatments like immunotherapy and targeted therapy. Our collective ability to intervene earlier and treat these diseases with greater molecular precision continues to transform outcomes, turning what was once a near-certain diagnosis into a manageable or even curable condition for millions.
Survival rates vary dramatically depending on the type of cancer, the stage at diagnosis, and the molecular profile of the tumor. Currently, the five-year survival rate for all cancers combined in the U.S. has reached approximately 70%, a substantial improvement from previous decades.
Patient characteristics play a critical role in both risk and prognosis.
Key factors include:
Inherited mutations in genes like BRCA1 and BRCA2 significantly increase the risk of specific cancers, such as breast and ovarian cancer. These are the genes the women in my family test negative for, but a genetic predisposition exists. Science just doesn’t know what gene or genes those are yet.
Environmental and Lifestyle Factors
Exposure to carcinogens (e.g., tobacco smoke, UV radiation, or certain chemicals) and chronic inflammation are major drivers of the genetic damage that leads to carcinogenesis. These are vital factors a care team would look at before diagnosing and treating a patient.
Age and Immune Status
The incidence of cancer generally increases with age, as the cumulative number of genetic mutations in the genome grows over time. Also, a patient’s immunosurveillance capacity, their immune system’s ability to identify and eliminate abnormal cells, is a vital determinant of whether a tumor will progress or be kept in a state of equilibrium.
Cancers are typically classified based on the tissue or cell type from which they originate.
These are the most common types, originating in the epithelial cells that line the inside or outside surfaces of the body (e.g., lung, breast, colon, and prostate cancers).
These arise in connective or soft tissues, such as bone, cartilage, fat, muscle, blood vessels, or fibrous tissue.
These are cancers of the blood-forming tissues, such as the bone marrow, leading to the overproduction of abnormal white blood cells.
These originate in the cells of the immune system (lymphocytes).
These begin in the tissues of the brain and spinal cord.
We are going to use one of a few metaphors to understand cancer. The first is to look at the human body as a massive, bustling city. We are made of trillions of cells, each acting like a specialized worker with a precise set of instructions; an instruction manual that tells them exactly when to work, when to rest, and when it’s time to retire.
Cancer begins when the “rulebook” in a single cell acquires a few nasty typos, or mutations. In a healthy scenario, if a cell is damaged, it has a built-in warning mechanism to either fix the error or trigger apoptosis, a form of programmed cell death that prevents the problem from spreading.
However, cancer emerges when a cell picks up a series of mutations that break these safety systems. Specifically, proto-oncogenes, which are the genes that normally act as a gas pedal for growth, get stuck in the “on” position, while tumor suppressor genes, which are the “brakes,” are disabled.
When these safety systems fail, the cell stops listening to “stop” signals and begins to multiply uncontrollably, forming a disorganized mass known as a primary tumor.
The Progression: From Mutation to Metastasis
As these rogue cells continue to divide, they undergo successive generations of mutations, becoming more aggressive and smarter. They eventually face an energy crisis; as the tumor grows larger than a few millimeters, the cells in the center begin to suffocate because they are too far from the body’s existing blood supply.
To survive, the tumor undergoes metabolic reprogramming, famously known as the Warburg Effect, where it switches to rapid fermentation for energy. This creates an acidic environment that helps the tumor break down the surrounding tissue. It then initiates angiogenesis, hijacking the body’s cardiac system by sending out chemical signals, specifically a protein called VEGF, to force the body to grow new blood vessels directly into the tumor.
It was not luck, but science that changed the fate of my mom and my aunt’s cancer prognosis; and that discovery began in the 1970s.
So before we delve further into specific cutting-edge treatments, let’s look at how far oncological science has come since 1975.
Curing Cancer Since 1975
The last 50 years of cancer treatment have evolved from blunt-force tools that caused significant collateral damage to smart therapies that train our own bodies to fight.
This transformation is a story of shifting our focus from attacking cells to understanding and correcting the genetic code that drives the disease.
In the 1970s, treatment was aggressive: if doctors could see a tumor, they removed it; if not, they tried to poison it. The 1971 National Cancer Act poured funding into research, leading to combination chemotherapy, which significantly improved survival despite being harsh on healthy cells. The 1972 arrival of CT scans then revolutionized how we visualized tumors.
By the 1980s and 90s, we realized cancer was a genetic software error. Identifying specific oncogenes, like HER2, led to the first targeted therapies in the late 90s. Drugs like Herceptin acted like a “lock and key,” attacking only cells with specific genetic errors. Simultaneously, surgery became less invasive, shifting from radical procedures to lumpectomies paired with targeted radiation.
The 2000s brought the precision revolution. After the 2003 completion of the Human Genome Project, we began treating cancer based on its unique molecular signature rather than just its location. Breakthroughs like Gleevec turned once-fatal leukemias into manageable conditions, while anti-angiogenesis drugs learned to starve tumors by cutting off their blood supply.
Since 2010, we have entered the age of immunotherapy. Checkpoint inhibitors take the “blinders” off T-cells so they can identify and attack hidden cancer, while CAR T-cell therapy turns a patient’s own cells into engineered “super-soldiers.” Meanwhile, liquid biopsies now detect cancer DNA in a simple blood draw, catching tumors years before they appear on traditional scans.
Today, our philosophy has transformed from “one size fits all” to personalized, precision medicine. We are outsmarting tumors by reading their code and empowering the body to defend itself. As a result, the five-year survival rate for all cancers combined has reached a historic 70%, and cancer mortality has declined by roughly 33% since 1991.
While new therapies provide steady, incremental improvements, often punctuated by extraordinary breakthroughs, they are complex. Because treatment efficacy depends heavily on the specific tumor profile, it is vital to consult an oncologist for personalized advice.
The Most Exciting Cutting Edge Advancement & Something You’ve Actually Heard Of: mRNA Therapy
Think of mRNA cancer therapy as a high-tech “wanted poster” for the immune system.
Normally, your immune system is great at spotting foreign invaders like viruses, but cancer cells are masters of disguise. They look like “model citizens” to your immune system, so they often go unnoticed. mRNA therapy is designed to unmask them.
What is mRNA Therapy?
To understand this, think of your cells as protein-making factories. DNA is the master blueprint kept in the office, but the mRNA (messenger RNA) is the actual instruction manual sent out to the factory floor to tell the workers which proteins to build.
In mRNA therapy, scientists create synthetic mRNA that carries a specific set of instructions. They wrap this manual inside a lipid nanoparticle, which is essentially a tiny, fatty bubble that acts like a microscopic delivery truck, to help it sneak past the cell’s outer defenses.
Once inside, the mRNA gives the cell a temporary assignment: “Build this specific protein.”
How mRNA is Used to Fight Cancer
In the context of cancer, we don’t want the body to build just any protein; we want it to build neoantigens.
These are unique markers found only on the surface of your specific cancer cells. By forcing the body to produce these markers, you are effectively handing the immune system a “wanted poster.” Your immune cells see these markers, recognize them as not belonging, and launch a precision attack against the tumor without harming healthy, normal cells.
Types of mRNA Vaccines
Personalized Vaccines
These are the “bespoke suits” of cancer treatment. Doctors sequence your specific tumor, identify the unique mutations in its DNA, and create an mRNA vaccine designed to attack only that exact mutation.
Shared Antigen Vaccines
These target common proteins that are found across many different patients who have the same type of cancer, making them a more “off-the-shelf” solution.
Therapeutic Applications
Beyond just vaccines, mRNA is being used to tell cells to produce cytokines (immune-boosting signals), tumor suppressors (the “brakes” for cancer), or even to help redesign your own cells to hunt for the cancer.
An Incredibly Exciting Cutting-Edge Cancer Treatment You Probably Haven’t Heard Of
Reengineering viruses to fight cancer is one of the most sci-fi frontiers in modern medicine. I first heard of this in 2012 when the very first treatments were in clinical trials. Essentially, we are taking some of the world’s most efficient invaders and rewriting their genetic code, so they work for us instead of against us.
Let’s switch from the city metaphor and reimagine your body as a high-security facility. Normally, a virus is like a hacker trying to break in and take over the system. But in OVs, scientists have essentially “hired the hacker.”
They’ve taken viruses, like the ones that cause the common cold or cold sores, and given them a very specific set of new instructions: “Ignore the healthy citizens, find the rogue cancer cells, and tear them down from the inside.”
How the Hacker Works
These viruses are genetically tweaked to be highly selective. They look for specific markers or weaknesses that only cancer cells have. Once a virus finds a tumor cell, it hitches a ride inside and starts making copies of itself until the cancer cell literally bursts. This process is called oncolysis.
But the real innovation happens after the burst. When the cancer cell is destroyed, it releases tiny biological red flags that were previously hidden inside. the cell. This triggers immunosurveillance, where your body’s own immune system finally realizes there’s a threat and joins the fight. It’s a two-pronged attack: the virus kills the cells directly, and then it calls in the cavalry, your T-cells, to finish the job.
The Heavy Hitters in the Field
We already have several of these reengineered invaders working in the real world. The most famous is T-VEC (brand name Imlygic), which is a modified herpes simplex virus used to treat melanoma. By tweaking the virus, scientists made it safe enough that it doesn’t cause disease in the patient, but remains deadly to the skin cancer. Other versions include Oncorine, which is used in China for head and neck cancers, and Delytact, a modified virus approved in Japan that tackles aggressive brain tumors called gliomas.
Arming Viruses and SHREAD Technology
The most exciting part of this research is how we are now arming these viruses. If a standard oncolytic virus is a soldier in an imagined anti-cancer army, an armed virus is a soldier carrying a specialized toolkit.
Researchers are now modifying these viruses to carry therapeutic genes directly into the heart of a tumor. For example, a virus can be engineered to produce cytokines, chemical signals that act like a megaphone, screaming for the immune system to come to a specific location. Others are designed to carry pro-apoptotic factors, which are essentially self-destruct codes that force the cancer cell to commit suicide.
One of the most mind-blowing new advancements is something called SHREAD technology (SHielded, REtargeted ADenovirus). Instead of just killing the cell, the virus acts like a 3D printer inside the tumor. Once it gets inside, it uses the cancer cell’s own machinery to produce high concentrations of specific drugs or antibodies right there on the spot.
This is a massive game-changer because it allows us to use powerful treatments that might be too toxic if they were circulating through your entire bloodstream, but are perfectly safe when they are “printed” and contained only within the tumor itself.
The Future of Oncolytic Viral Therapies
We are still learning how to make these viruses even stealthier so the immune system doesn’t accidentally kill the hired hacker before it reaches the tumor. Scientists are experimenting with different delivery systems, like hiding the virus inside a protective coating or even using messenger cells to ferry the virus directly to a metastatic site.
As we move toward more personalized medicine, the goal is to create viruses that are custom-coded for a patient’s specific genetic mutations. We are shifting away from the old era of poisoning the whole body and moving toward a future where we use the very things that once made us sick to help us heal.
Oncological Drugs & Mixed Therapies That Are Getting Us Closer to Curing Major Cancers, Tailored to Your Specific Situation
When we look at the modern medical landscape, we see a move from one-size-fits-all poisons to a much more sophisticated toolkit. In addition to reengineering viruses, we are now repurposing old drugs and using smart molecules to correct the genetic mutations that cause cancer. Here are just a few of those tools in the toolkit!
These treatments act like a high-tech pair of glasses for your immune system. Jemperli and Libtayo are checkpoint inhibitors that strip away the invisibility cloak cancer cells use to hide, while BCG (an old TB vaccine) wakes up local immune cells to attack tumors sitting on the surface of organs like the bladder.
The “Plumbing Blockers” Are Angiogenesis Inhibitors: Avastin and HIV Protease Inhibitors
To grow, tumors need a constant supply of nutrients, so they grow their own blood vessels. Avastin and repurposed HIV drugs like Viracept and Norvir act as cardiovascular blockers, cutting off these supply lines (angiogenesis) and effectively starving the tumor into submission.
These are smart drugs designed to fix specific genetic typos. Voranigo targets the IDH mutation in brain tumors, Ojemda shuts down growth signals in pediatric gliomas, and Tyrosine Kinase Inhibitors (TKIs) have turned once-fatal leukemias into manageable conditions by blocking the specific grow signal at the molecular level.
The “Repurposed Disruptors”: Ivermectin, Vistide, Azidothymidine (AZT), and Auranofin
This group involves taking drugs originally meant for parasites, viruses, or other ailments and using them to disrupt cancer’s machinery. They work by putting a lock on cell proliferation and triggering apoptosis, the cell’s built-in self-destruct sequence we talked about before, which cancer cells usually try to ignore.
The “Living Homing Beacons” Are Gene Therapy: HSV1-TK, Valacyclovir, and Flt3L
This is a two-step trap for cancer. First, a virus sneaks a specific gene, known as HSV1-TK, into the tumor to act as a homing beacon; then, a common antiviral like Valacyclovir is introduced. The drug only becomes a toxic killer inside the cells tagged with that specific gene, while Flt3L acts as a recruiter to bring in a massive wave of immune soldiers to finish the job.
These treatments target how cancer cells eat and breathe. TG02 and Iwilfin break the metabolic processes tumors need to thrive, while Forskolin can actually reprogram aggressive cells into a dormant, sleepy state so they stop dividing.
The “DNA Disruptors”: Temodar, Methotrexate, and Combination Chemotherapy
These are the refined descendants of traditional treatment. Temodar and Methotrexate work by creating glitches in the cancer’s DNA so it can’t make copies of itself, while Combination Chemotherapy uses a cocktail of these weapons to hit the tumor from multiple angles at once, preventing it from building up resistance.
The “Mimics”: BO-112
This is a clever virus-mimicking drug. It doesn’t use a real virus, but it tricks the tumor into thinking it has a massive viral infection. This biological “head-fake” causes the immune system to go into a high-alert state, leading to a scorched-earth attack on the cancer cells.
These drugs and treatments are exciting to say the least, but we do have to dial back the excitement and keep our vision clear. Drug resistance is a big deal.
Drug resistance is one of the most frustrating hurdles in cancer care. You can think of a tumor not just as a static lump, but as a constantly evolving, intelligent population that will use everything in its arsenal to evade your body’s defenses and keep growing.
When we hit it with a drug, we aren’t just killing cells; we are forcing the tumor to undergo a rapid, artificial evolution. The survivors of that first treatment are the ones who were already mutant enough to ignore the drug, and they quickly take over the neighborhood.
Also, targeted therapies can inadvertently cause tumor cells to evolve, creating new sub-groups of cancer that are no longer sensitive to the treatment. This often necessitates the use of complex drug combinations rather than single agents to effectively counter the cancer’s ability to adapt.
Resistance happens through a combination of genetic tricks and cellular survival strategies.
A tumor is a crowded city of billions of cells. Even before treatment starts, a few cells might have random genetic mutations that happen to make them immune to our current drug. When we treat the patient, we kill off the sensitive cells, leaving the resistant ones to grow into a new, tougher tumor. This is often due to steric interference, where a mutation actually changes the physical shape of a protein so the drug can no longer lock onto it, much like a key that no longer fits a damaged lock.
Rewiring and Bypass
If we block one specific growth road, cancer cells are experts at finding a detour. They can activate redundant pathways, recruiting similar proteins to do the same job, or activate parallel routes to keep growing. Sometimes, a drug can even trigger paradoxical activation, where the very inhibitor we use to stop a signal ends up accidentally speeding up a different part of the cellular machinery.
The Stem Cell Problem
Within every tumor, there is a small, elite subpopulation called Cancer Stem-Like Cells (CSCs). These cells are master survivors. They can enter a state of dormancy, meaning they essentially go to sleep and become invisible to chemotherapy, which only targets fast-growing cells. They also have supercharged detoxification systems (like overexpressing ALDH enzymes) that neutralize drugs before they can do any damage, and they are incredibly efficient at repairing their own DNA after radiation exposure.
The Hostile Niche
The Tumor Microenvironment (TME) acts like a fortress. Surrounding cells, such as cancer-associated fibroblasts, secrete growth factors that shield the tumor. They also produce exosomes, tiny delivery bubbles, that carry resistance-promoting signals to other cells. By suppressing the immune system’s ability to detect them, these tumors become effectively cloaked from T-cell attacks.
The Human Verified Reality Check
Treating the Whole System
Beyond the biology of mutations, a patient’s mental and social environment is a critical variable in cancer care. We cannot treat a tumor in a vacuum; biological resilience is fueled by social connection.
Chronic Stress Keeps the Body in Fight-or-Flight Mode
It floods the system with cortisol. As an immunosuppressant, cortisol effectively dulls the immune system, making it harder to hunt down rogue cells. Supportive environments, like advocacy groups, lower these stress hormones, creating a chemically calmer internal landscape where the immune system can focus on the cancer.
Trust also acts as medicine.
When a patient feels supported, the brain releases endorphins and dopamine, which interact with immune cells to optimize their activity. This emotional context, part of the placebo/nocebo spectrum, directly influences biological output. Furthermore, patients with strong support systems are statistically more likely to adhere to complex medication schedules, preventing the inconsistent dosing that often allows tumors to evolve drug resistance.
Support groups function as collective intelligence nodes, where patients exchange real-world data on side-effect management and nutrition that clinical charts often miss. This social buffering keeps the patient mentally fortified, providing the stamina required for long-term recovery.
In This Era of Precision Medicine, the Doctor’s Role is Shifting From Simple Prescriber to interpreter
While a tumor is a master of biological evasion, it cannot account for a patient who is mentally and socially fortified. The most advanced treatment isn’t just a drug—it’s the combination of molecular science and a patient empowered to fight alongside their care team.
This Precision Comes with a Staggering Price Tag.
While we have moved to sophisticated targeted therapies, the financial reality of these modern treatments creates a deep, concerning divide in global healthcare access.
The Great Cost Divide
The gap in cost between traditional treatments and modern smart drugs is astounding.
For example, a standard eight-week course of traditional fluorouracil-based chemotherapy might cost around $60. In stark contrast, an eight-week regimen using modern monoclonal antibodies—which are lab-grown proteins designed to target specific cancer cells—can cost up to $30,000.
This financial chasm isn’t just about the drugs themselves; it extends to the diagnostic tools needed to use them. Advanced imaging like PET/CT scanners can cost over $2 million per machine, with high ongoing maintenance costs that make them virtually impossible to operate in economically disadvantaged regions.
Why Are These Drugs So Expensive?
Several factors drive high prices while Curing Cancer. First, the cost of research and development is astronomical. It is estimated that bringing a single new drug to market costs anywhere from $1.3 billion to $3.2 billion. This figure accounts for the astronomical cost of capital and, crucially, the fact that many drugs fail during clinical trials. Manufacturers often frontload their pricing, setting high launch prices to recoup these massive investments before patents expire or price negotiation policies kick in.
Unlike traditional small-molecule pills, which are relatively easy to manufacture, modern biological agents are complex to develop and require costly, ongoing maintenance during production. Companies argue that these high prices are the only way to sustain the innovation cycle necessary to keep finding new cures.
Barriers to Access and the Socio-Economic Hurdle
These costs create a harsh reality: a patient’s socio-economic status often determines whether they can afford the continuous dosing required to actually reach a cure. In many low-income countries, these biological therapies are simply unavailable. This creates a geography of survival, where the quality of care and the likelihood of successful treatment are dictated more by the patient’s bank account or their country’s GDP than by the biological nature of the cancer itself.
To address cost and access issues, governments are starting to intervene. In the US, the Inflation Reduction Act (IRA) introduced the Medicare Drug Price Negotiation Program. This allows the government to negotiate prices for certain high-expenditure drugs that have held long-term monopolies without competition. While this represents a fundamental change in how the industry forecasts profits, it is a complex balancing act that tries to lower costs without stifling the future development of new drugs.
Researchers are working on several fronts to bridge the access gap
Small-Molecule Substitutes: Scientists are racing to develop cheaper, chemical-based pills that can mimic the effect of expensive biological antibodies.
Dosing Innovations: Newer drugs are being designed with unique dosing schedules. For instance, some treatments can now be administered every six weeks rather than weekly, which reduces the burden of clinic visits and lowers overall healthcare costs.
Ultimately, while the current oncology market is defined by a stark disparity between traditional, affordable medicine and high-cost, high-precision treatments, the goal is clear. By fostering innovation in cheaper chemical alternatives and smarter healthcare policy, the scientific community is working to ensure that these life-saving advancements don’t remain a luxury but become a universal standard of care.
One of the few unifying factors across all of humanity is the desire to cure cancer.
The fight is primal, and every human is at risk. Maybe someday, we’ll expand this fight on a global scale, utilizing collaborative science that can move these discoveries along at a faster rate. Oh well. One can dream!
Thank You For Spending This Time With Me Today
All Content, Audio, Visuals & Imagery Are Property of JWPhD
Copyright 2026
Don’t forget to check out Human Verified on Social!
Comments